BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3519413)

  • 1. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
    Dimitriadis G; Karaiskos C; Raptis S
    Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
    Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
    J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
    García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
    Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
    Hayakawa T; Noda A; Kondo T; Okumura N
    Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modification of carbohydrate metabolism and oral glucose tolerance test in type II diabetics using the glucosidase inhibitor acarbose].
    Schwartzkopff W; Calder D
    Med Welt; 1984 Feb; 35(6):169-74. PubMed ID: 6369065
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
    Robertson J; Nelson R; Kass P; Neal L
    Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
    Bischoff H
    Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition of intestinal alpha glucosidases in the therapy of diabetes mellitus].
    Fölsch UR; Lembcke B
    Internist (Berl); 1991 Dec; 32(12):699-707. PubMed ID: 1823561
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic potential of alpha-glucosidase-inhibitors.
    Fölsch UR
    Hepatogastroenterology; 1982 Apr; 29(2):47-8. PubMed ID: 7044933
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
    Yamamoto M; Otsuki M
    Metabolism; 2006 Apr; 55(4):533-40. PubMed ID: 16546485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
    Dimitriadis GD; Tessari P; Go VL; Gerich JE
    Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
    Ledermann H; Höxter G
    Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
    Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
    Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acarbose--a new therapeutic principle in diabetes mellitus therapy].
    Schöffling K; Hillebrand I
    Dtsch Med Wochenschr; 1981 Aug; 106(35):1083-4. PubMed ID: 6114844
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of acarbose as monotherapy in NIDDM patients.
    Deerochanawong C; Serirat S; Kornthong P
    J Med Assoc Thai; 1996 Feb; 79(2):69-75. PubMed ID: 8868016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of an alpha-glucosidase inhibitor, acarbose, on blood glucose and serum lipids in streptozotocin-induced diabetic rats.
    Yamashita K; Sugawara S; Sakairi I
    Horm Metab Res; 1984 Apr; 16(4):179-82. PubMed ID: 6373545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acarbose, an unduly neglected antidiabetic drug].
    Iványi J; Gyimesi A
    Orv Hetil; 1996 Dec; 137(49):2737-41. PubMed ID: 9679608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.